GlassScriptPhysician profile
Robert A Bazylak
NPI 1285614263
$15,335.06
in general payments reported to CMS, 2019-2025
44 companies · $1,997 in 2025
The $1,997 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,337 · 2020: $958 · 2021: $1,680 · 2022: $2,072 · 2023: $2,810 · 2024: $2,481 · 2025: $1,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,288.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,787.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,337.72 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,301.47 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,235.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,132.56 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $894.45 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $830.17 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $808.76 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $756.85 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $692.63 | 2019-2024 | Xarelto |
| Amgen INC. | $636.06 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $482.48 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.51 | 2019-2024 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $336.66 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $310.29 | 2019-2025 | Trintellix |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bazylak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.